Navigation Links
Shire Reaches Agreement in Principle With U.S. Government
Date:2/1/2013

PHILADELPHIA, February 1, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that it has reached an agreement in principle to resolve the previously disclosed civil investigation into Shire's U.S. sales and marketing practices relating to ADDERALL XR®, VYVANSE® and DAYTRANA®[1].  

The investigation was led by the U.S. Attorney's Office for the Eastern District of Pennsylvania, and Shire disclosed the investigation in 2009.  The agreement also addresses sales and marketing practices relating to LIALDA® and PENTASA® pursuant to a subsequent voluntary disclosure made by Shire.  

Shire cooperated with the U.S. Government throughout the process that led to this agreement in principle.  Shire has recorded a $57.5M charge in the fourth quarter of 2012, comprised of the agreement in principle amount, interest and costs.  

The agreement in principle is subject to change until this matter is finally resolved.  Discussions between Shire and the U.S. Government are ongoing to establish a final resolution to the investigation.

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

  • Behavioral Health and Gastro Intestinal conditions
  • Rare Diseases
  • Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

--------------------------------------------------

1. DAYTRANA® is a trademark of Noven Pharmaceutical Inc.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

For further information please contact:

Investor Relations Eric Rojas erojas@shire.com +1-781-482-0999 Sarah Elton-Farr seltonfarr@shire.com +44(0)1256-894157 Media Jessica Mann (Corporate) jmann@shire.com +44(0)1256-894-280


'/>"/>
SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
2. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
3. Shire Changes its NASDAQ Ticker Symbol to SHPG
4. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
5. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
6. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
7. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
8. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
9. Mold from Sandy Remains a Problem in Rockaways; My Cleaning Products Reaches Out to Help with Its Green Mold Removal Spray
10. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
11. Cold Adds Up to Sandy Victims' Mold Problems; Optimal Chemical Reaches Out to Help by Advising the Use of Molderizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... ... August 11, 2017 , ... A staple in the community for ... will incorporate important key elements including a new digital marketing strategy and updated logo. ... them, Bill Miller has partnered with the South Texas Blood & Tissue Center for ...
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... ... food production, and, in particular, more natural alternatives to synthetic ingredients,” said Matt ... of Third Wave, with the established manufacturing presence and know-how of Biorigin will ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three Philadelphia ... August 14th through the 16th, the University City Science Center will kick off ... 2016, provides Philadelphia-based middle school educators an opportunity for professional development related to ...
(Date:8/10/2017)... ... ... Each year in the United States more than 300,000 people are hospitalized for ... even worse, the one-year mortality rate is high, ranging from 12 percent to 37 ... Medical Center (Sacramento) and Second Xiangya Hospital of the Central-South University (Hunan, China) might ...
Breaking Biology Technology:
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):